Results 51 to 60 of about 121,674 (149)

Cytokine Release Syndrome After Modified CAR-NK Therapy in an Advanced Non-small Cell Lung Cancer Patient: A Case Report

Cell Transplantation, 2022
Use of chimeric antigen receptors (CARs), as an immune cell therapy, has generated excellent clinical outcomes against hematologic tumors in recent years.
Xiaodi Zhang, Yuying Guo, Yinghua Ji, Yan Gao, Min Zhang, Yanting Liu, Wuling Zhu, Ping Lu   +7 more
doaj   +1 more source

Engineered T Cell Therapies from a Drug Development Viewpoint

Engineering, 2019
Cancer is one of the leading causes of death worldwide. Recent advances in cellular therapy have demonstrated that this platform has the potential to give patients with certain cancers a second chance at life.
Fang Chen, Joseph A. Fraietta, Carl H. June, Zhongwei Xu, J. Joseph Melenhorst, Simon F. Lacey   +5 more
doaj   +1 more source

CAR-CD34 (+) hematopoietic stem/progenitor cells produced in vivo protect against thoracic aortic aneurysm and dissection

Nature Communications
Thoracic aortic aneurysm and dissection is one of the most devastating cardiovascular diseases, with limited medical intervention options. This study aims to develop chimeric antigen receptor-engineered CD34+ hematopoietic stem/progenitor cells and ...
Kaiwen Zhao, Yuzhen He, Renqi Yao, Shuangshuang Li, Lingxu Kong, Jinzhu Niu, Zan Zeng, Pengcheng Du, Hongqiao Zhu, Rong Zhao, Taiping Liang, Zaiping Jing, Jian Zhou   +12 more
doaj   +1 more source

Tisagenlecleucel Model‐Based Cellular Kinetic Analysis of Chimeric Antigen Receptor–T Cells

CPT: Pharmacometrics & Systems Pharmacology, 2019
Tisagenlecleucel is a chimeric antigen receptor–T cell therapy that facilitates the killing of CD19+ B cells. A model was developed for the kinetics of tisagenlecleucel and the impact of therapies for treating cytokine release syndrome (tocilizumab and ...
Andrew M. Stein, Stephan A. Grupp, John E. Levine, Theodore W. Laetsch, Michael A. Pulsipher, Michael W. Boyer, Keith J. August, Bruce L. Levine, Lori Tomassian, Sweta Shah, Mimi Leung, Pai‐Hsi Huang, Rakesh Awasthi, Karen Thudium Mueller, Patricia A. Wood, Carl H. June   +15 more
doaj   +1 more source

Chimeric antigen receptor T-cell therapy and bispecific antibodies in the treatment of lymphoma for human immunodeficiency virus-infected patients: A systematic review

SAGE Open Medicine
Background: Chimeric antigen receptor T-cell therapy has emerged as a highly effective treatment for relapsed and refractory lymphomas; however, its application in individuals with human immunodeficiency virus remains underexplored.
Alejandra Viera Plasencia, Jeremy I. Purow, Julia Steger, Alexander Brown-Whalen, Henna Qadri, Nicolas Duque Clavijo, Marco Ruiz-Andia   +6 more
doaj   +1 more source

Redirected Primary Human Chimeric Antigen Receptor Natural Killer Cells As an “Off-the-Shelf Immunotherapy” for Improvement in Cancer Treatment

Frontiers in Immunology, 2017
Primary human natural killer (NK) cells recognize and subsequently eliminate virus infected cells, tumor cells, or other aberrant cells. However, cancer cells are able to develop tumor immune escape mechanisms to undermine this immune control.
Olaf Oberschmidt, Stephan Kloess, Ulrike Koehl   +2 more
doaj   +1 more source

Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response

Nature Communications, 2019
Supraphysiological T cell activation by chimeric antigen receptor (CAR) contributes to T cell exhaustion and adverse events in CAR T cell therapies. Here the authors engineer a synthetic antigen receptor that integrates into the endogenous TCR complex ...
Patrick A. Baeuerle, Jian Ding, Ekta Patel, Niko Thorausch, Holly Horton, Jessica Gierut, Irene Scarfo, Rashmi Choudhary, Olga Kiner, Janani Krishnamurthy, Bonnie Le, Anna Morath, G. Christian Baldeviano, Justin Quinn, Patrick Tavares, Qi Wei, Solly Weiler, Marcela V. Maus, Daniel Getts, Wolfgang W. Schamel, Robert Hofmeister   +20 more
doaj   +1 more source

Management of chimeric antigen receptor T-cell-related toxicity of a patient affected by cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, followed by an intestinal perforation: a case report

Journal of Medical Case Reports
Background Mantle cell lymphoma is a diverse B-cell lymphoma with varying clinical behaviors. Treating relapsed or refractory mantle cell lymphoma is challenging, with Bruton’s tyrosine kinase inhibitors proving effective but not curative.
G. Menardi, A. Castellino, C. Castellino, M. E. Bersia, E. Grande, G. Fraternali, M. Massaia, C. Fruttero   +7 more
doaj   +1 more source

Application progress on immunotherapy with chimeric antigen receptor T cell in patients with hematological malignancies

Huli yanjiu, 2020
Reviewing application progress on immunotherapy with chimeric antigen receptor T cell（CAR⁃T） in patients with hematological malignancies from 4 aspects,such as collection,pretreatment,note on cell reinfusion,and treatment complication of chimeric antigen
MENG Rui, XU Li, WAN Ying
doaj  

CHIMERIC ANTIGEN RECEPTOR [PDF]

, 2020
PULÉ MARTIN, CORDOBA SHAUN, THOMAS SIMON, ONUOHA SHIMOBI, CHEAN LIM WEN, MA BIAO, FERRARI MATHIEU   +6 more
  +10 more sources